Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 19/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 17/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697761 | 1.00 | F11 (0.49) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL29227916 | 0.90 | F11 (0.48) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL30995017 | 0.90 | F11 (0.48) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL30995015 | 0.90 | F11 (0.48) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL29479366 | 0.86 | F11 (0.48) | F11KLKB1CYP3A4 | |
| SCHEMBL21357425 | 0.86 | F11 (0.48) | F11KLKB1CYP3A4 | |
| SCHEMBL30623106 | 0.84 | F11 (0.48) | F11KLKB1CYP3A4F2F10 | |
| SCHEMBL30656519 | 0.84 | F11 (0.39) | F11KLKB1CYP3A4NR1I2 | |
| SCHEMBL29089482 | 0.84 | F11 (0.39) | F11KLKB1CYP3A4NR1I2 | |
| SCHEMBL24633281 | 0.83 | F11 (0.50) | F11KLKB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111770917-B | Process for the preparation of two compounds | 拜耳股份公司 | 2023-09-26 | — | — | CN | claimed |
| US-11542245-B2 | Preparative process | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-03 | — | — | US | claimed |
| EP-3765452-B1 | PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES | BAYER AG (DE) | 2022-04-13 | — | — | EP | claimed |
| US-20210017152-A1 | PREPARATIVE PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | claimed |
| EP-3765452-A1 | PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-01-20 | — | — | EP | claimed |
| CN-111770917-A | Two 4- { [ (2S) -2- {4- [ 5-chloro-2- (1H-1,2, 3-triazol-1-yl) phenyl ] -5-methoxy-2-oxopyridin-1 (2H) -yl } butyryl ] amino } -2-fluorobenzamide derivatives | 拜耳股份公司 | 2020-10-13 | — | — | CN | claimed |
| WO-2019175043-A1 | PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-19 | — | — | WO | claimed |
| CN-116903585-A | Oxo-pyridine derivative and application thereof in medicine | 天津药物研究院有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-111770917-B | Process for the preparation of two compounds | 拜耳股份公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11542245-B2 | Preparative process | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-03 | — | — | US | disclosed |
| US-11542245-B2 | Preparative process | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-03 | — | — | US | disclosed |
| EP-3765452-B1 | PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES | BAYER AG (DE) | 2022-04-13 | — | — | EP | disclosed |
| CN-112028877-B | Alkoxy pyridone compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3889147-A1 | 4-({(2S)-2-[4-{5-CHLORO-2-[4-(TRIFLUOROMETHYL)-1H-1,2,3-TRIAZOL-1-YL]PHENYL}-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL]BUTANOYL}-AMINO)-2-FLUOROBENZAMIDE ACETONE AND ITS USE | Bayer Aktiengesellschaft (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210017152-A1 | PREPARATIVE PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017152-A1 | PREPARATIVE PROCESS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| EP-3765452-A1 | PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-01-20 | — | — | EP | disclosed |
| CN-112028877-A | Alkoxy pyridone compound and preparation method and application thereof | 江西济民可信集团有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-111770917-A | Two 4- { [ (2S) -2- {4- [ 5-chloro-2- (1H-1,2, 3-triazol-1-yl) phenyl ] -5-methoxy-2-oxopyridin-1 (2H) -yl } butyryl ] amino } -2-fluorobenzamide derivatives | 拜耳股份公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2019175043-A1 | PREPARATIVE PROCESS OF TWO 4-{[(2S)-2-{4-[5-CHLORO-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUOROBENZAMIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542245-B2 | Preparative process | F13A1, F13B, TUBA3C | F11 12/4885KLKB1 3280/4885CYP3A4 154/4885 |
| US-20210017152-A1 | PREPARATIVE PROCESS | F13A1, F13B, TUBA3C | F11 12/4885KLKB1 3280/4885CYP3A4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.